ReviewProtoplasma2026
Triple identity of medicinal plant-derived extracellular vesicles.
Review in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammation - a blessing and a curse.Protoplasma · 2026Article
- Immune cell-derived circulating extracellular vesicles mediate metabolic dysfunction in preclinical and clinical type 1 diabetes.Acta diabetologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Medicinal plant-derived extracellular vesicles (MPDEVs) are nanoscale vesicles secreted by medicinal plant cells. They are enriched in diverse functional components and function as natural mediators that facilitate intercellular communication and regulate multiple physiological processes. Owing to their unique biological activities and delivery capabilities, these vesicles have emerged as a frontier research hotspot. Recent studies have demonstrated that MPDEVs exhibit excellent biocompatibility and cross-species delivery potential and can be engineered to encapsulate small-molecule compounds for use as drug delivery vectors. Remarkably, MPDEVs also display notable intrinsic therapeutic effects and can be directly applied as natural therapeutic agents in various disease models. Furthermore, MPDEVs can be co-administered with conventional therapeutic drugs to strengthen their efficacy and improve bioavailability. This article systematically summarizes the biogenesis, composition, and functional properties of MPDEVs and emphasizes their broad application potential, characterized by a triple identity as intelligent carriers, natural therapeutic agents, and synergistic treatment systems. Nonetheless, the translation of MPDEVs from laboratory research to clinical application is impeded by several critical challenges, including source heterogeneity, the absence of specific biomarkers for efficient purification and identification, and a lack of standardized quality control procedures. Accordingly, this paper also highlights these core limitations and outlines future development directions aimed at facilitating clinical translation and industrial deployment. The objective is to provide a comprehensive reference and theoretical framework to support overcoming these constraints and to contribute to the advancement of MPDEVs into reliable and scalable biomedical tools.
Indexed as
Identifiers
42432268What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.